3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
3
Phase 1
2
Phase NA
1
Phase 3
1
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Carcinoma, Non-Small-Cell Lung
23
Breast Neoplasms
22
Colorectal Neoplasms
14
Ovarian Neoplasms
12
Lung Neoplasms
10
Neoplasm Metastasis
9
Stomach Neoplasms
8
Neoplasms
8
Nasopharyngeal Carcinoma
8
Leukemia, Myeloid, Acute
7
Triple Negative Breast Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
6
Rectal Neoplasms
6
Fallopian Tube Neoplasms
6
Recurrence
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Esophageal Squamous Cell Carcinoma
5
Uterine Cervical Neoplasms
4
Prostatic Neoplasms
4
Lymphoma, Non-Hodgkin
4
Leukemia
4
Head and Neck Neoplasms
4
Esophageal Neoplasms
4
Carcinoma, Ovarian Epithelial
4
Pancreatic Neoplasms
3
Neoplasms by Site
3
Lymphoma, Large B-Cell, Diffuse
3
Adenocarcinoma
3
Urinary Bladder Neoplasms
2
Multiple Myeloma
2
Interventions
Cisplatin
6
Pemetrexed
4
Carboplatin
3
Nivolumab
2
Ipilimumab
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
ranpirnase
1
raltitrexed
1
durvalumab
1
atezolizumab
1
Vinorelbine
1
Vincristine
1
Talc
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy
1
Psychiatric Rehabilitation
1
Platinum
1
Mitomycin
1
Injections
1
Gemcitabine
1
Fentanyl
1
Drug Therapy
1
Doxorubicin
1
Cerebral Decortication
1
Analgesia
1
1,2-diaminocyclohexaneplatinum II citrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Mesothelioma, Malignant
×
Drug Therapy
×
Clear all
NCT03710876
2026-04-21
INFINITE
Ferring Ventures Limited
Phase 3
Completed
53 enrolled
23 charts